The Gillian Institute Offers Breakthrough, FDA-Cleared, Non-Invasive UltraShape™ System for Immediate Fat Cell Destruction

Share Article

Innovative Fat Reduction Technology Generates Visible Results Within Two-Weeks Of Treatment

Kimberly Short, MD, an Indianapolis based board-certified plastic surgeon is pleased to announce the addition of UltraShape™, a revolutionary treatment recently FDA cleared for fat cell destruction, to The Gillian Institute. In direct response to growing demand for non-surgical solutions that help patients feel more confident and comfortable in their skin, the practice enhances its treatment offerings with this top-performing body-shaping solution from aesthetic medical device leader Syneron Candela.

The UltraShape System is the first and only non-invasive fat reduction treatment that uses pulsed focused ultrasound to immediately and comfortably destroy fat cells, resulting in measurable outcomes in as little as two weeks.

The UltraShape device works by emitting waves of focused pulsed ultrasonic energy, converging at a closely confined area where patients want to target stubborn fat. Ultrasound is comfortably delivered to the treatment area, while keeping surrounding tissue, nerves and muscles intact and undamaged. Fat cells are destroyed and eliminated by the body’s natural processes as soon as two weeks after treatment resulting in very visible immediate reduction.

"We are excited to offer our patients UltraShape as nothing non-invasive works faster,” states Dr. Short. “UltraShape’s patented technology allows us to precisely deliver ultrasound energy with extraordinary accuracy, allowing us to target and destroy fat cells immediately. Unlike traditional ultrasound technology, UltraShape distributes energy in pulses rather than in a single continuous delivery, which can be painful. The UltraShape result is a quick, safe and comfortable treatment experience without discomfort, lumps, bumps or soreness associated with many other non-invasive fat reduction treatments.” Treatments take less than an hour and patients can go right back to their normal activities without any disruption.

In the randomized, controlled clinical study of UltraShape, which was performed at three clinical sites in the US and one site outside of the US, a total of 150 subjects were treated and followed for up to four months. Ninety four percent of patients saw a measurable circumferential reduction with ninety percent of patients being satisfied with their treatment outcomes. This is one of the largest studies ever performed in the area of non-invasive aesthetics.

UltraShape is a very versatile device that is effective for the reduction of fat deposits that are resistant to diet and exercise. UltraShape is FDA cleared for fat cell destruction and is used to improve body shape and contour.

The UltraShape device has been used in over 300,000 procedures worldwide, with an excellent safety and efficacy profile.

To learn more about UltraShape, our practice or to request a consultation, call us at (317) 913-3260, or visit us at

The Gillian Institute
8455 Clearvista Pl
Indianapolis, IN 46256
Phone: (317) 913-3260

About Syneron
Syneron Medical Ltd. is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela.

For additional information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sheila Arway
+1 (917) 664-9823
Email >